Hugel, Inc. · KRX:145020
Hugel — J.P. Morgan Healthcare Conference 2026
19 slides from Hugel's conference presentation, Jan 15, 2026
Slide 1: J.P. Morgan Healthcare Conference
January 15, 2026 Presenter J.P. Morgan Healthcare Carrie Strom, Global CEO Conference 01
Slide 2: Disclosures
DISCLOSURES A SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This document is for the presentation of Hugel, Inc.(“Company”) and provided for the convenience of investors only. This presentation may contain "forward-looking statements" - that is, statements related to future, not past, events. In
Slide 3: Transforming into a Global Leader
KOREAN MEDICAL AESTHETICS COMPANY Transforming into a Global Leader INVESTING IN THE U.S. Target 2028 revenue hybrid sales model enables rapid adoption with K-AESTHETICS LEADER KRW 900 bn profitability with toxin as key anchor with industry-leading operating margins #1 IN KOREA protecting leadership
Slide 4: Next Generation Management Team
NEXT GENERATION MANAGEMENT TEAM Global Operating Model, Building U.S. Operations, Deep Korean Expertise Carrie Strom President and Global Chief Executive Officer Daniel Chang Korea Chief Executive Officer Hyoungjin Moon, MD Hiring best in Vice President, U.S. Chief Medical Officer class talent in Co
Slide 5: Hugel K-Aesthetics: Comprehensive Product Portfolio
HUGEL K-AESTHETICS Comprehensive Product Portfolio Cosmeceutical 14% REVENUE contribution in 9M2025 Filler & Skin Booster 32% REVENUE contribution in 9M2025 Botulinum Toxin 53% REVENUE contribution in 9M2025 CONTOURING LIFTING RELAXING VOLUMIZING CHEEK PDO THREAD FOREHEAD GLABELLA LINES CROW’S FEET
Slide 6: Toxins: Underpenetrated and Growing Market
TOXINS Underpenetrated and Growing Market 10M 6% PROCEDURES GROWTH IN ANNUALLY1 PATIENT SPEND3 #1 MID SINGLE DIGIT PROCEDURE FOR CONSUMER PROVIDERS1 PENETRATION PRIMARY CONSUMER BARRIER TO ADOPTION:2 1. American Society of Plastic Surgeons Statistics Report, 2024 COST 2. ASDS Consumer Survey on Cosm
Slide 7: A Winning Global Brand Value Proposition
A WINNING GLOBAL BRAND VALUE PROPOSITION 1 PRODUCT THE K-AESTHETIC NEUROTOXIN 2 SCIENCE WELL STUDIED CLINICAL PROFILE 3 PRACTICE PRACTICE-CENTRIC VALUE Born in Korea’s world-leading Robust scientific evidence Streamlined, transparent aesthetic market, Letybo® supporting efficacy and safety. pricing
Slide 8: K-Aesthetics: The Emerging Global Standard in Aesthetic Care
K-AESTHETICS: THE EMERGING GLOBAL STANDARD IN AESTHETIC CARE For decades, South Korea has set K-beauty’s emphasis on prevention U.S. consumers increasingly see the pace for beauty innovation, and natural results underpins the Korea as the authority on subtle, creating a market projected to reach K-a
Slide 9: Letybo: The #1 Leader in K-Aesthetics
LETYBO® THE #1 LEADER IN K-AESTHETICS #1 market share position in Korea for 10 consecutive years Proven Track Record The Only Korean >15-year of track record 68 global approvals Toxin Approved in the for safety and quality expanding to >80 U.S., China & Europe assurance since launch by 2028 Sources:
Slide 10: Letybo Medical Credibility
LETYBO® MEDICAL CREDIBILITY A Well-Studied Clinical Profile Comparable Dilution and Administration to leading BoNT-A products Reliable outcomes validated in clinical studies in 1,000+ patients Vial Amount of Diluent* Resulting Dose Added Units per 0.1 mL 50U 1.25 mL 4 Units Safety and efficacy profi
Slide 11: Letybo Practice-Centric Value
LETYBO® PRACTICE-CENTRIC VALUE High capacity, end-to-end Premium quality brand offered at Optionality for practices manufacturing enables strong meaningful value versus market leaders gross margins for Hugel Premium Price Brands Manufacturer Gross Margin1 (avg) ➔ If discount is passed onto patients,
Slide 12: U.S. Strategy to Drive Profitable Growth
U.S STRATEGY TO DRIVE PROFITABLE GROWTH With Innovative “Hybrid” Sales Model Hybrid model leverages existing partner while Hybrid model differs from past toxin launches, simultaneously building direct sales channel enabling both market uptake and profitability Forecasted Market Share (M/S) and the U
Slide 13: New U.S. Investments in Marketing & Medical Affairs
NEW U.S. INVESTMENTS IN MARKETING & MEDICAL AFFAIRS Field Based K-Aesthetics Commercial Customer Data generation Field Based Medical Sales teams consumer & Scientific presence experiences hosted with publications Science Liaison and customer at leading medical at Korea HQ and and IITs teams marketin
Slide 14: Bolster Korean Leadership Position
BOLSTER KOREAN LEADERSHIP POSITION Via Commercial Execution and Portfolio Expansion Increase Cross-Selling Product Innovation through targeted field execution to maintain premium toxin positioning Number of Products Current Cross Sell Rate 1 66% 300 unit vial enables price competitiveness in mid tie
Slide 15: Expand Market Share in International Markets
EXPAND MARKET SHARE IN INTERNATIONAL MARKETS Leveraging Global Operating Model & Local Initiatives Hugel building a playbook that While customizing strategies can be leveraged globally based on specific markets GLOBAL BRAND & VALUE PROP Launch new skin boosters OPTIMIZE MEDICAL DISTRIBUTOR AFFAIRS &
Slide 16: Hugel Home Grown Skinbooster Platform
HUGEL HOME GROWN SKINBOOSTER PLATFORM Expanding into the U.S. & Other Key Markets Global Skin Booster Market Expected to Reach $3B by 20301 Hugel Skin Booster Platform is powered by a curated selection of clinically proven ingredients across the continuum of aesthetic care TOPICAL OTC / PROFESSIONAL
Slide 17: Hugel Pipeline for Market Expansion
HUGEL PIPELINE FOR MARKET EXPANSION Leverage Business Development to Fill Gaps in Key Markets Category Product Preclinical Clinical Registration Launch Target Letybo® (Type A) Currently available in 60 markets 2026 Saudi Arabia, Türkiye, Mexico, India Toxin Pure Toxin Type E 2027 Low BDDE Korea Fill
Slide 18: Hugel Highlights
HUGEL HIGHLIGHTS Innovative U.S. hybrid sales model enables rapid adoption with profitability Large, underpenetrated global aesthetics market Expanding global market share across priority with strong K-Aesthetic growth tailwinds international markets Neurotoxin anchor product uniquely positioned as
Slide 19: Investor Relations Contacts
Ray Kim Minji Oh Haley Kim Celine Kim Contact: IR Group Head, IRO IR Team Lead IR Manager IR Manager [email protected] 19